Human trophoblastic cell surface antigen 2 (Trop2) is upregulated in cancers compared to normal tissues. Researchers from the University of Texas MD Anderson Cancer Center recently aimed to assess the clinical significance of Trop2 in small bowel adenocarcinoma (SBA).
Bladder small-cell carcinoma can be divided into different subtypes depending on the expression of neuroendocrine (NE) markers such as POU2F3, NEUROD1 and ASCL1. Single-cell RNA sequencing previously found a distinct subpopulation with high expression of 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-2 (PLCG2) with pro-metastatic features and poor prognosis. The aim of a newer study was to evaluate the expression of PLCG2 in bladder NE tumors and correlate it with prognostic utility.
Researchers from the University of Pittsburgh Medical Center and affiliated organizations aimed to validate a novel marker of duodenal neuroendocrine tumors (DNETs), NKK6.2.
Limited data exist on checkpoint inhibition that targets the early activation phase of adaptive immunity. B-and T-lymphocyte attenuator (BTLA) blockade is known to enhance and broaden CD8+ T-cell responses to a target antigen.
Hepatocellular carcinoma (HCC) is one of the leading causes of cancer deaths among men and its rate of incidence is rapidly increasing in women. The development of new therapeutics targeting hepatic cancer stem cells using herbal medicine could shed light on the treatment of HCC.
The mTORC2 complex plays an important role in the PI3K/AKT/mTOR pathway, allowing activation of AKT and contributing to the development of BRAF-mutated (BRAFm) melanomas and their resistance to treatments. Researchers from Inserm aimed to identify new candidates for targeting the mTORC2 complex in melanoma, with focus on one principal protein of this complex, MAPKAP1 (also known as SIN1).
RSS
